New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohort
Authors' conclusion
Considering the amount of vaccine doses administered during the evaluation period we overall detected a limited number of cases. We noted a clear prevalence of autoinflammatory conditions and seronegative manifestations. The great majority of patients had mild features and showed a good response to therapy.
Study context
- Population
- Patients presenting with a rheumatic disease within 30 days after an anti-COVID-19 vaccine dose, Padova University Hospital, May–September 202176.6% BNT162b2
- Participants
- 30 patients
- Exposure
- New onsets vs Flares
- New onsetsn = 24
- Flaresn = 6
- Outcome
- RD following COVID-19 vaccination: onset, manifestations and response to therapy
Methodological detailssingle-centre, 9-month follow-up, WHO adverse event following immunisation (AEFI) surveillance guidelines, Patients regularly re-evaluated by telemedicine or face-to-face visit
- Single-centre
- 9-month follow-up
- WHO AEFI surveillance guidelines
- Patients regularly re-evaluated by telemedicine or face-to-face visit
Main finding
As reported in the abstract
- Mean time to RD onset/flare (days)
- 12±9
- Inflammatory arthritis
- 40.0%
- Rheumatic polymyalgia
- 33.3%
- AOSD
- 13.3%
- Complete response to first- or second-line therapy at last FU (9.6±2.2 months)
- 83.3%
- Partial response at last FU
- 13.3%
- Still active disease at last FU (1 patient)
- 3.3%
Observational data: associations, not effects.
Original publication
New onset and flare of rheumatic diseases following COVID-19 vaccination are mild and respond well to treatment: 9-month follow-up data from a single centre cohort. Clin Exp Rheumatol. Published 13 December 2021. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →